- Investing.com
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.
Regulatory Catalyst | Pending BLA approval for Avance Nerve Graft could grant 12 years of market exclusivity, potentially establishing it as the standard of care in target markets |
Market Expansion | AxoGen's TAM revised from $2.7B to $5.6B, with plans to enter prostate market. Strategic focus on four key markets promises diverse growth opportunities |
Financial Milestones | Company projects 17% YoY revenue growth, expects profitability this year, and aims to be net cash flow positive in 2025, showcasing strong financial health |
Nerve Repair Pionee | AxoGen leads in peripheral nerve injury solutions, with innovative products driving impressive 37% stock return and 17.2% revenue growth in the last yea |

Metrics to compare | AXGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAXGNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −123.2x | −3.6x | −0.5x | |
PEG Ratio | 2.42 | 0.01 | 0.00 | |
Price / Book | 15.0x | 3.7x | 2.6x | |
Price / LTM Sales | 8.6x | 3.1x | 3.2x | |
Upside (Analyst Target) | 6.2% | 54.2% | 44.7% | |
Fair Value Upside | Unlock | 12.2% | 5.7% | Unlock |